Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicare Beneficiary Preservation of Choice Act of 2011
Client: AETNA INC · Firm: AETNA INC.
(1) Public Law 111-148 The Patient Protection and Affordable Care Act; (2) Public Law 111-152 Health Care and Education Reconciliation Act of 2010; and (3) H.R. 1580 Medicare Beneficiary Preservation of Choice Act of 2011 (expands Medicare open enrollment and disenrollment opportunities). General Medicare/Medicaid reimbursement issues, such as the sustainable growth ration (SGR) and efforts to improve and expand care delivery models. including for dual eligibles.
To provide for expedited consideration by the Supreme Court of certain actions challenging the constitutionality of certain provisions of the Patient Protection and Affordable Care Act.
Client: AETNA INC · Firm: AETNA INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AETNA INC via AETNA INC.
2012 · first_quarter · Q1
(1) Public Law 111-148 The Patient Protection and Affordable Care Act; and (2) Public Law 111-152 Health Care and Education Reconciliation Act of 2010. Issues related to the health reform laws implementation, including medical loss ratio (MLR), taxes, exchanges, essential health benefits, affordability, health information technology, transparency and employer regulations.
(1) Public Law 111-148 The Patient Protection and Affordable Care Act; and (2) Public Law 111-152 Health Care and Education Reconciliation Act of 2010. Issues related to the health reform laws implementation, including medical loss ratio (MLR), taxes, exchanges, essential health benefits, affordability, health information technology, transparency and employer regulations.
Source: Senate LDA
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
To provide for expedited consideration by the Supreme Court of certain actions challenging the constitutionality of certain provisions of the Patient Protection and Affordable Care Act.
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
To provide for expedited consideration by the Supreme Court of certain actions challenging the constitutionality of certain provisions of the Patient Protection and Affordable Care Act.
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
To provide for expedited consideration by the Supreme Court of certain actions challenging the constitutionality of certain provisions of the Patient Protection and Affordable Care Act.
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
To provide for expedited consideration by the Supreme Court of certain actions challenging the constitutionality of certain provisions of the Patient Protection and Affordable Care Act.
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); S. 848 (Disclosure of Medicare provider data); HR 1031 (Medicaid)
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); s. 848 (Diasclosure of Medicare Provider data); HR 1031.
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); S. 848 (Disclosure of Medicare provider data); HR 1031 (Medicaid).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S.137 (mechanism for HHS/states to covvect excessive insurance rates); HR 605 (repeal FSA/HSA OTC restrictions); S. 312 (Repeals OTC restrictions); HR 2010/S.1089 (Expand use of HSAs); HR 1206; (excluse commissions from MLR); HR 1050 (creates AHPs); HR 371 (Cross-State selling)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to covvect excessive insurance rates);
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to covvect excessive insurance rates);
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
Access to Professional Health Insurance Advisors Act of 2011
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
Access to Professional Health Insurance Advisors Act of 2011
Client: AETNA INC · Firm: AETNA INC.
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
Access to Professional Health Insurance Advisors Act of 2011
Client: AETNA INC · Firm: AETNA INC.
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S.137 (mechanism for HHS/states to covvect excessive insurance rates); HR 605 (repeal FSA/HSA OTC restrictions); S. 312 (Repeals OTC restrictions); HR 2010/S.1089 (Expand use of HSAs); HR 1206; (excluse commissions from MLR); HR 1050 (creates AHPs); HR 371 (Cross-State selling)
Access to Professional Health Insurance Advisors Act of 2011
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
Access to Professional Health Insurance Advisors Act of 2011
Client: AETNA INC · Firm: AETNA INC.
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
Access to Professional Health Insurance Advisors Act of 2011
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
Access to Professional Health Insurance Advisors Act of 2011
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
Access to Professional Health Insurance Advisors Act of 2011
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S.137 (mechanism for HHS/states to covvect excessive insurance rates); HR 605 (repeal FSA/HSA OTC restrictions); S. 312 (Repeals OTC restrictions); HR 2010/S.1089 (Expand use of HSAs); HR 1206; (excluse commissions from MLR); HR 1050 (creates AHPs); HR 371 (Cross-State selling)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
National Strategic and Critical Minerals Policy Act of 2011
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
National Strategic and Critical Minerals Policy Act of 2011
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
National Strategic and Critical Minerals Policy Act of 2011
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S.137 (mechanism for HHS/states to covvect excessive insurance rates); HR 605 (repeal FSA/HSA OTC restrictions); S. 312 (Repeals OTC restrictions); HR 2010/S.1089 (Expand use of HSAs); HR 1206; (excluse commissions from MLR); HR 1050 (creates AHPs); HR 371 (Cross-State selling)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to covvect excessive insurance rates);
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to covvect excessive insurance rates);
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S.137 (mechanism for HHS/states to covvect excessive insurance rates); HR 605 (repeal FSA/HSA OTC restrictions); S. 312 (Repeals OTC restrictions); HR 2010/S.1089 (Expand use of HSAs); HR 1206; (excluse commissions from MLR); HR 1050 (creates AHPs); HR 371 (Cross-State selling)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S.137 (mechanism for HHS/states to covvect excessive insurance rates); HR 605 (repeal FSA/HSA OTC restrictions); S. 312 (Repeals OTC restrictions); HR 2010/S.1089 (Expand use of HSAs); HR 1206; (excluse commissions from MLR); HR 1050 (creates AHPs); HR 371 (Cross-State selling)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to covvect excessive insurance rates);
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to covvect excessive insurance rates);
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S.137 (mechanism for HHS/states to covvect excessive insurance rates); HR 605 (repeal FSA/HSA OTC restrictions); S. 312 (Repeals OTC restrictions); HR 2010/S.1089 (Expand use of HSAs); HR 1206; (excluse commissions from MLR); HR 1050 (creates AHPs); HR 371 (Cross-State selling)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: AETNA INC · Firm: AETNA INC.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
Medicare Prescription Drug Savings and Choice Act of 2011
Client: AETNA INC · Firm: AETNA INC.
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); s. 848 (Diasclosure of Medicare Provider data); HR 1031.
Medicare Prescription Drug Savings and Choice Act of 2011
Client: AETNA INC · Firm: AETNA INC.
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number);
Medicare Prescription Drug Savings and Choice Act of 2011
Client: AETNA INC · Firm: AETNA INC.
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number);
Medicare Prescription Drug Savings and Choice Act of 2011
Client: AETNA INC · Firm: AETNA INC.
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); S. 848 (Disclosure of Medicare provider data); HR 1031 (Medicaid).
Medicare Prescription Drug Savings and Choice Act of 2011
Client: AETNA INC · Firm: AETNA INC.
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); S. 848 (Disclosure of Medicare provider data); HR 1031 (Medicaid)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S.137 (mechanism for HHS/states to covvect excessive insurance rates); HR 605 (repeal FSA/HSA OTC restrictions); S. 312 (Repeals OTC restrictions); HR 2010/S.1089 (Expand use of HSAs); HR 1206; (excluse commissions from MLR); HR 1050 (creates AHPs); HR 371 (Cross-State selling)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
HR 1583 (Mccarran-Ferguson). S. 819 (mandate autism coverage). HR 1253 (new plan disclosure rules). HR 1691/S. 688 (prohibit plan rescissions and establish minimum length of hospital stays for cancer patients) HR 1558/S. 623 (prohibit pre-existing condition exclusions; also HR 1619, S. 643, HR 1092) S. 442/ HR 1085 (to prohibit aggregate lifetime dollar limit) S> 697/HR 1721 (Long Term Care) H 975 (mammography mandate); HR 1339 (Mandate to cover deformities)
HR 1583 (Mccarran-Ferguson). S. 819 (mandate autism coverage). HR 1253 (new plan disclosure rules). HR 1691/S. 688 (prohibit plan rescissions and establish minimum length of hospital stays for cancer patients) HR 1558/S. 623 (prohibit pre-existing condition exclusions; also HR 1619, S. 643, HR 1092) S. 442/ HR 1085 (to prohibit aggregate lifetime dollar limit) S> 697/HR 1721 (Long Term Care) H 975 (mammography mandate); HR 1339 (Mandate to cover deformities)
(1) Public Law 111-148 The Patient Protection and Affordable Care Act; (2) Public Law 111-152 Health Care and Education Reconciliation Act of 2010; and (3) H.R. 1580 Medicare Beneficiary Preservation of Choice Act of 2011 (expands Medicare open enrollment and disenrollment opportunities). General Medicare/Medicaid reimbursement issues, such as the sustainable growth ration (SGR) and efforts to improve and expand care delivery models. including for dual eligibles.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Personnel Management (OPM), SENATE, Treasury, Dept of
AETNA INC via AETNA INC.
2011 · fourth_quarter · Q4
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number);
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to covvect excessive insurance rates);
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AETNA INC via AETNA INC.
2011 · second_quarter · 2A
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); S. 848 (Disclosure of Medicare provider data); HR 1031 (Medicaid).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AETNA INC via AETNA INC.
2011 · third_quarter · Q3
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); s. 848 (Diasclosure of Medicare Provider data); HR 1031.
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S.137 (mechanism for HHS/states to covvect excessive insurance rates); HR 605 (repeal FSA/HSA OTC restrictions); S. 312 (Repeals OTC restrictions); HR 2010/S.1089 (Expand use of HSAs); HR 1206; (excluse commissions from MLR); HR 1050 (creates AHPs); HR 371 (Cross-State selling)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of, White House Office
AETNA INC via AETNA INC.
2011 · second_quarter · Q2
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); S. 848 (Disclosure of Medicare provider data); HR 1031 (Medicaid)
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to correct excessive insurance rates); HR 605 (repeal FSA/HSA OTC restriction); S. 312 (Repeals OTC restriction); HR 2010/S. 1089 (expand use of HSAs); HR 1206 (exclude Commissions from MLR calculation). HR 1050 (Creates AHPs-Association Health Plans); HR 371 (Cross-state selling).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AETNA INC via AETNA INC.
2011 · first_quarter · Q1
S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number);
HR 1050 (allows for Association Health Plans free from state mandated benefits); HR 346 (allows for national insurance marketplace via cross-state purchsing of coverage); HR 416/S. 137 (mechanism for HHS/states to covvect excessive insurance rates);
HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).
AETNA INC via AETNA INC.
2010 · fourth_quarter · Q4
HR 1 American Recovery and Reinvestment Act (increase FMAP, and moratorium on Medicaid regulations) HR 2, SCHIP. HR 904/S 547 (Medicaid drug rebates) HR 684/S. 330 (to establish government-run PDP) S. 266 (government run negotiation of drug prices in Medicare) S. 75 (to promote generic drugs in Medicare). S. 677 (to means-test Part B Premiums). S. 1832 (to regulate Part D plan prices). S.960 (Medicare Buy in); HR 3961 ("Doc Fix"); S. 2128 (MM Fraud & Abuse); S. 1776 (SGR). HR 3590/HR 48
HR 1204 (Antitrust exception for Pharmacists). HR 1493 (Antitrust exemption for physicians). HR 1 (COBRA coverage subsidy; comparative effectiveness, wellness, HIT finding and privacy). HR 1427/S. 726/ HR 1548 (FDA pathwqy to approve generic Biopharmaceutical medicines). S. 369/HR 1706 (generic/brand "settlements"). S. 93 (establish FEHBP for small employers. S. 391/ HR 1321 (National health insurance). HR 676/S. 703 (single-payer health plan) HR 193 (Medicare "for all"). A. 1796, S. 1679 (Health Care Reform); HR 676/S. 703 (Single payer): PL 111-148; PL 111-152.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HR 1583 (Mccarran-Ferguson). S. 819 (mandate autism coverage). HR 1253 (new plan disclosure rules). HR 1691/S. 688 (prohibit plan rescissions and establish minimum length of hospital stays for cancer patients) HR 1558/S. 623 (prohibit pre-existing condition exclusions; also HR 1619, S. 643, HR 1092) S. 442/ HR 1085 (to prohibit aggregate lifetime dollar limit) S> 697/HR 1721 (Long Term Care) H 975 (mammography mandate); HR 1339 (Mandate to cover deformities)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE